Patents by Inventor Thomas Eissing

Thomas Eissing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE
    Publication number: 20260060966
    Abstract: The disclosure refers to a method of preventing or treating heart failure in a patient using (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide (INN: Finerenone).
    Type: Application
    Filed: November 10, 2025
    Publication date: March 5, 2026
    Inventors: Peter KOLKHOF, Patrick SCHLÖMER, Arno FRITSCH, Antonieta BOMFIM WIRTZ, So-Young KIM, Thomas EISSING, John Joseph Valentine MCMURRAY, Scott D. SOLOMON, Bertram PITT, Thomas WENDL, Achim Erhard FRITSCH, Pardeep JHUND
  • METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE
    Publication number: 20260027091
    Abstract: The disclosure refers to a method of preventing or treating heart failure in a patient using (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide (INN: Finerenone).
    Type: Application
    Filed: July 17, 2025
    Publication date: January 29, 2026
    Inventors: Peter KOLKHOF, Patrick SCHLÖMER, Arno FRITSCH, Antonieta BOMFIM WIRTZ, So-Young KIM, Thomas EISSING, John Joseph Valentine MCMURRAY, Scott D. SOLOMON, Bertram PITT, Thomas WENDL, Achim Erhard FRITSCH, Pardeep JHUND
  • METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE
    Publication number: 20250313559
    Abstract: The disclosure refers to a method of preventing or treating heart failure in a patient using (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide(INN: Finerenone).
    Type: Application
    Filed: January 3, 2025
    Publication date: October 9, 2025
    Applicant: Bayer Aktiengesellschaft
    Inventors: Peter KOLKHOF, Patrick SCHLÖMER, Arno FRITSCH, Antonieta BOMFIM WIRTZ, So-Young KIM, Thomas EISSING, John Joseph Valentine MCMURRAY, Scott D. Solomon, Bertram PITT
  • METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE
    Publication number: 20250302811
    Abstract: The disclosure refers to a method of preventing or treating heart failure in a patient using (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide (INN: Finerenone).
    Type: Application
    Filed: April 3, 2025
    Publication date: October 2, 2025
    Inventors: Peter KOLKHOF, Patrick SCHLÖMER, Arno FRITSCH, Antonieta BOMFIM WIRTZ, So-Young KIM, Thomas EISSING, John Joseph Valentine MCMURRAY, Scott D. SOLOMON, Bertram PITT, Thomas WENDL, Achim Erhard FRITSCH, Pardeep JHUND
  • GENOTYPE- OR PHENOTYPE-BASED DRUG FORMULATION
    Publication number: 20170326081
    Abstract: The invention relates to a combination of two or more pharmaceutically active substances, of which at least one is a metabolic product (“metabolite”) of the other (“parent substance”), wherein in particular the dosages thereof are selected such that genotypically or phenotypically related variability in the conversion of the parent substance to the metabolite in particular individuals is compensated for.
    Type: Application
    Filed: June 16, 2017
    Publication date: November 16, 2017
    Inventors: Stefan Willmann, Thomas Eissing, Kristin Dickschen
  • GENOTYPE- OR PHENOTYPE-BASED DRUG FORMULATION
    Publication number: 20150174082
    Abstract: The invention relates to a combination of two or more pharmaceutically active substances, of which at least one is a metabolic product (“metabolite”) of the other (“parent substance”), wherein in particular the dosages thereof are selected such that genotypically or phenotypically related variability in the conversion of the parent substance to the metabolite in particular individuals is compensated for.
    Type: Application
    Filed: May 27, 2013
    Publication date: June 25, 2015
    Applicant: BAYER TECHNOLOGY SERVICES GmbH
    Inventors: Stefan Willmann, Thomas Eissing, Kristin Dickschen